Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00309244 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up
A Phase 3 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 677
- Enrollment target
NCT00309244: Completed Phase 3 study, sponsored by Mannkind Corporation.
NCT00309244 is a Phase 3 study that has completed, run by Mannkind Corporation. The registered enrollment target is 677 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00309244, a Phase 3 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 677 participants
- Enrollment target
Study Summary
The purpose of this 13 month study (12 month treatment period and 1 month follow-up period) is to determine whether inhaled insulin is safe and effective in the treatment of type 2 diabetes.
Interventions
- DRUG Technosphere® Insulin Inhalation Powder
- DRUG 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 677 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
What the finished NCT00309244 record still lists
NCT00309244 is an interventional study that assigns participants to a tested intervention. The registered 677 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 2 interventions - of which Technosphere® Insulin Inhalation Powder is the first listed.
NCT00309244 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00309244 about?
NCT00309244 is a clinical study titled "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up". The purpose of this 13 month study (12 month treatment period and 1 month follow-up period) is to determine whether inhaled insulin is safe and effective in the treatment of type 2 diabetes.
What is the current status of trial NCT00309244?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 677 participants. The study started on 2006-02. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00309244?
The interventions under investigation include: Technosphere® Insulin Inhalation Powder (DRUG), 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin) (DRUG).
Who is sponsoring clinical trial NCT00309244?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00309244's enrollment target sits among peer trials
677 537th of 2000 higher than 1,464 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05372484 · 678 participants · NA
Rice Technologies for Cervical Cancer Screening and Diagnosis
- NCT06436924 · 678 participants
Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Device Implant Procedural Day
- NCT07227337 · 676 participants · NA
Being Safe, Healthy, And Positively Empowered (BSHAPE) Intervention Study
- NCT04788277 · 675 participants
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia